Eli Lilly is on a meteoric rise, with analysts eyeing a potential $2 trillion valuation by 2031. Already raking in over $30 billion annually—mostly from blockbuster GLP-1 drugs like tirzepatide—it’s expanding into new frontiers: liver disease, sleep apnea, and high blood pressure. New approvals for Alzheimer’s and ulcerative colitis promise billions more, while strategic acquisitions and AI-driven drug discovery are fueling its pipeline. Despite a pricey stock, its relentless growth and diversified future make it a compelling bet for the long haul.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
